



Jeff

CERTIFICATE OF MAILING

I hereby certify that this paper is being deposited with the U.S. Postal Service as first class mail on the date indicated below in an envelope addressed to: Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Name of Person Mailing: CHRIS MYERS

Signature: *Chris Myers* Date: *March 14, 2005*

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Information Disclosure Statement Address to: Commissioner of Patents PO Box 1450 Alexandria, VA 22313-1450	First Named Inventor	Jian Jeffrey Chen
	Application Number	10/715,666
	Filing Date	November 18, 2003
	Group Art Unit	1624
	Examiner	Kahsay Habte
	Attorney Docket No.	R0144B-REG
	Title	Diazinopyrimidines

Sir:

Transmittal for Information Disclosure Statement

Transmitted herewith for filing in the above-entitled patent application is an Information Disclosure Statement, in compliance with 37 CFR §1.97, which may be material to the patentability of the subject patent application.

- [X] Attached are:
- Form 1449, "Information Disclosure Statement By Applicants," with copy of each reference cited
 - Return postcard
- [X] The Information Disclosure Statement is being submitted more than three (3) months after the filing date and after the mailing date of the first Office Action on the merits, but before a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first, without certification under 37 CFR 1.97(e). The \$180.00 fee set forth in § 1.17(p) is authorized below.

Deposit Account Authorization

- [X] Please charge \$ 180.00 to Deposit Account No. 18-1700 and charge any additional fees that may be required to Deposit Account No. 18-1700. A duplicate of this Transmittal Letter is enclosed.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.


Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Grant D. Green', written over a horizontal line.

Grant D. Green
Reg. No. 31,259
Attorney for Applicants

Roche Palo Alto LLC
3431 Hillview Avenue - M/S A2-250
Palo Alto, CA 94304
Direct Phone (650) 855-5311

Date: March 14, 2005



Please type a plus sign (+) inside this box →



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANTS

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	10/715,666
Filing Date	November 18, 2003
First Named Inventor	Jian Jeffrey Chen
Group Art Unit	1624
Examiner Name	Kahsay Habte
Attorney Docket Number	R0144B-REG

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Yoshinari et al., "Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: Involvement of the p38 mitogen-activated protein kinase pathway," Critical Care Med (2001) pp 628-634, Vol. 29:3	
	C2	Bhatia et al., "Role of inflammatory mediators in the pathophysiology of acute respiratory distress syndrome" Journal of Pathology (2004) pp 145-156, Vol 202	
	C3	Aringer et al., "Safety and Efficacy of Tumor Necrosis Factor Alpha Blockade in Systemic Lupus Erythematosus" Arthritis & Rheumatism (Oct 2004) pp 3161-3169, Vol 50:10	
	C4	Goldring et al., "The Role of Cytokines in Cartilage Matrix Degeneration in Osteoarthritis" Clinical Orthopaedics and Related Research (2004) pp S27-S36, No. 427S	
	C5	Di Giovine et al., "Urate Crystals Stimulate Production of Tumor Necrosis Factor Alpha from Human Blood Monocytes and Synovial Cells" Journal of Clin. Invest. (April 1991) pp 1375-1381, Vol. 87	
	C6	Muller, Thomas. "CPI-1189 Centaur" Current Opinion in Investigational Drugs (2002) pp 1763-1767, Vol. 3:12	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.